Revolution Medicines Inc.

1 day ago · defenseworld.net

Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Alan Sandler sold 341 shares of Revolution Medicines stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $67,940.84. Following the completion of the transaction, the insider directly owned 52,868 shares of the

1 day ago · defenseworld.net

Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) CFO Jack Anders sold 4,053 shares of the company's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $807,519.72. Following the completion of the transaction, the chief financial officer owned 119,216

4 days ago · fool.com

Revolution Medicines validated its approach to treating certain cancers with a recent regulatory approval. The company's new medicine might become the top-prescribed treatment in its indication.

6 days ago · defenseworld.net

Concurrent Investment Advisors LLC bought a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,534 shares of the company's stock, valued at approximately $475,000. Several other large investors have also modified their

6 days ago · globenewswire.com

REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company's RAS(ON) multi-selective inhibitor, for treatment-naïve metastatic pancreatic adenocarcinoma (PDAC) in combination with gemcitabine and nab-paclitaxel (GnP), a multiagent chemotherapy regimen widely used in treating patients with PDAC. RASONQUE was recently approved by the U.S. FDA for the treatment of adult patients with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

11 days ago · defenseworld.net

Arizona State Retirement System boosted its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 17.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 46,382 shares of the company's stock after buying an additional 6,986 shares during the quarter. Arizona State

17 days ago · marketbeat.com

Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.

17 days ago · zacks.com

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

24 days ago · marketbeat.com

Revolution Medicines NASDAQ: RVMD said the U.S. Food and Drug Administration has approved daraxonrasib under the brand name RASONQUE for certain adults with metastatic pancreatic adenocarcinoma.

24 days ago · fool.com

It's a cancer medication with immense potential. In clinical testing, the pill was shown to double the survival rate of pancreatic cancer patients.